Fig. 1.

EerI has anticancer activity and can synergize with bortezomib. (A and B) Cytotoxic activities of bortezomib (BZM) and EerI in HBL-2 and JEKO-1 cells. Cells were treated as indicated for 48 h, and cell viability was measured by a MTT assay. Error bar, SD (n = 3). (C) As in (A) and (D) as in (B) except that primary cells isolated from CLL patients and healthy donors (PMBC) were used. (E) Synergistic action of EerI and bortezomib. HBL-2 cells were treated with the indicated concentrations of EerI, bortezomib, or a combination of the two drugs (EerI, Bottom; BZM, Top). The combination index at IC50 is < 0.1, suggesting a strong synergy between the two agents.